88 completed, 88 recruiting, 72 active not recruiting, 31 terminated. 205 Phase 2, 91 Phase 1, 69 Phase 3, 9 Not applicable, 8 Phase 4.
Follow daratumumab: new trials by email Literature Review of daratumumab trials Research Report on daratumumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse Biospecimen Collection, Bone Marrow Biopsy, Carfilzomib - Recurrent Multiple Myeloma, Refractory Multiple Myeloma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 80 | 2027-05-22 | 2026-10-20 |
| Testing an Experimental Approach to Treat Patients With Plasma Cell Leukemia, The QUANTUM Trial Autologous Hematopoietic Stem Cell Transplantation, Biospecimen Collection, Bone Marrow Aspiration - Plasma Cell Leukemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 74 | 2027-04-20 | 2026-10-07 |
| MMulti-Immune HR; Multi-Target Immunotherapy for High-Risk Multiple Myeloma teclistamab+daratumumab followed by talquetamab+daratumumab followed by duration treatment with daratumumab and lenalidomide extended/maintenance, melphalan (MEL)-based hematopietic stem cell transplantation (HSCT) followed by drug therapy - Multiple Myeloma (MM) | Phase 2 | Not yet recruiting | University of Arkansas | 50 | 2027-03-01 | 2026-09-02 |
| A Trial to Evaluate Safety and Efficacy of Anitocabtagene Autoleucel Versus Standard of Care in Newly Diagnosed Multiple Myeloma Anitocabtagene autoleucel, Daratumumab, Bortezomib - Newly Diagnosed Multiple Myeloma | Phase 3 | Not yet recruiting | Kite, A Gilead Company | 600 | 2027-01-01 | 2026-10-21 |
| Comparing Bispecific Antibody Treatment to Autologous Stem Cell Transplant for Newly Diagnosed, Standard Risk Multiple Myeloma Daratumumab and Recombinant Human Hyaluronidase, Lenalidomide, Bortezomib - Multiple Myeloma (MM) | Phase 2 / Phase 3 | Not yet recruiting | Alliance for Clinical Trials in Oncology | 920 | 2026-12-23 | 2026-10-22 |
| A Study to Evaluate Adverse Events and Change in Disease Activity With Injected Etentamig Plus Oral Pomalidomide Versus Standard Therapies in Adults With Relapsed or Refractory Multiple Myeloma Etentamig, Pomalidomide, Daratumumab - Relapsed or Refractory Multiple Myeloma | Phase 3 | Not yet recruiting | AbbVie | 520 | 2026-11-30 | 2026-07-27 |
| Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis Etentamig, Daratumumab, Cyclophosphamide - Amyloid Light Chain (AL) Amyloidosis | Phase 3 | Not yet recruiting | AbbVie | 370 | 2026-11-29 | 2026-08-28 |
| CM336 Plus Daratumumab and Lenalidomide in Transplant-Ineligible Newly Diagnosed Multiple Myeloma CM336 (BCMA/CD3 bispecific antibody), Daratumumab, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Institute of Hematology & Blood Diseases Hospital, China | 24 | 2026-10-15 | 2026-09-21 |
| FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma FT836 CAR T cells (1 x 10^8 cells per dose), FT836 CAR T cells (3 x 108 cells per dose), FT836 CAR T cells (up to 9 x 108 cells per dose) - Relapse Multiple Myeloma, Refractory Multiple Myeloma | Phase 1 | Not yet recruiting | Medical College of Wisconsin | 12 | 2026-10-01 | 2026-08-10 |
| A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned Ramantamig, Daratumumab, Lenalidomide - Multiple Myeloma | Phase 3 | Recruiting | Janssen Research & Development, LLC | 1000 | 2026-09-09 | 2026-10-06 |
| A Study Comparing Treatment With Teclistamab and Talquetamab Versus Daratumumab and Lenalidomide in Patients With Multiple Myeloma After Stem Cell Transplant Who Still Have Detectable Disease Teclistamab, Talquetamab, Daratumumab (Subcutaneously) - Multiple Myeloma (MM) | Phase 3 | Not yet recruiting | Polish Myeloma Consortium | 248 | 2026-09-01 | 2026-07-31 |
| Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL) Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration - Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma | Phase 2 / Phase 3 | Not yet recruiting | Children's Oncology Group | 1708 | 2026-08-28 | 2026-07-30 |
| A Open-Label Phase in Participants With Multiple Myeloma Dexamethasone, IBI3003, Lenalidomide - Multiple Myeloma | Phase 2 | Not yet recruiting | Innovent Biologics (Suzhou) Co. Ltd. | 120 | 2026-08-15 | 2026-08-14 |
| ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma Elranatamab (PF-06863135), Daratumumab and Hyaluronidase-fihj, Lenalidomide - Multiple Myeloma, Newly Diagnosed Multiple Myeloma | Phase 2 | Not yet recruiting | Massachusetts General Hospital | 160 | 2026-08-01 | 2026-06-23 |
| Inobrodib, Pomalidomide and Dexamethasone Versus Standard Available Therapy in Relapsed or Refractory Multiple Myeloma InoPd, Investigator's choice of SAT - Multiple Myeloma Refractory, Multiple Myeloma in Relapse | Phase 3 | Recruiting | CellCentric Ltd. | 450 | 2026-08-01 | 2026-08-19 |
| Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype Dexamethasone, Bortezomib, LENALIDOMIDE - Multiple Myeloma, Triple Negative Breast Cancer | Phase 1 | Recruiting | Andrew Hantel, MD | 90 | 2026-07-30 | 2026-08-17 |
| A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants With Relapsed or Refractory Multiple Myeloma AZD4045, Daratumumab, Aldesleukin - Relapsed or Refractory Multiple Myeloma | Phase 1 / Phase 2 | Recruiting | AstraZeneca | 101 | 2026-07-27 | 2026-10-15 |
| CD38 mAb Induction + Azathioprine Maintenance for Chronic Active AMR in Kidney Transplant Recipients CD38, Azathioprine (AZA), Standard Triple Immunosuppression Maintenance - Kidney Transplantation, Antibody-mediated Rejection | Not applicable | Not yet recruiting | wujianyong | 20 | 2026-07-15 | 2026-07-21 |
| Personalising Treatment for Myeloma Patients Based on Initial Response to NHS Treatment and Their Overall Fitness Level Daratumumab, Lenalidomide, Dexamethasone - Multiple Myeloma (MM), Plasma Cell Leukemia (PCL) | Phase 3 | Recruiting | University of Leeds | 1226 | 2026-07-01 | 2026-07-15 |
| Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation Daratumumab, Lenalidomide, Bortezomib - Newly Diagnosed Multiple Myeloma, Multiple Myeloma | Phase 2 | Withdrawn | UNC Lineberger Comprehensive Cancer Center | 2026-07-01 | 2026-06-09 |
Showing 20 of 349. Sign in to see all of them.
Multiple Myeloma (231) · Recurrence (29) · Immunoglobulin Light-chain Amyloidosis (16) · Neoplasms, Plasma Cell (16) · Neoplasms (14) · Amyloidosis (9) · Leukemia, Myeloid, Acute (9) · Lymphoma, Non-Hodgkin (7) · Neoplasm, Residual (6) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (6) · Purpura, Thrombocytopenic, Idiopathic (6) · Smoldering Multiple Myeloma (6) · Lymphoma (5) · Hematologic Neoplasms (4) · Leukemia, Plasma Cell (4)
Janssen Research & Development, LLC (36) · Mayo Clinic (13) · Institute of Hematology & Blood Diseases Hospital, China (12) · AbbVie (9) · M.D. Anderson Cancer Center (9) · Celgene (8) · Hellenic Society of Hematology (6) · PETHEMA Foundation (6) · Stichting European Myeloma Network (6) · Bristol-Myers Squibb (5) · City of Hope Medical Center (5) · Memorial Sloan Kettering Cancer Center (5) · National Cancer Institute (NCI) (5) · GlaxoSmithKline (4) · Hoffmann-La Roche (4)
United States (202) · France (73) · Spain (72) · China (55) · Italy (53) · Germany (50) · Australia (45) · Canada (45) · United Kingdom (44) · Greece (41) · Netherlands (41) · Japan (39) · Belgium (36) · South Korea (35) · Poland (33)
Evangelos Terpos, Prof (3) · Lei Zhang (3) · Alfred Chung, MD (2) · Andrew Yee, MD (2) · Fernando Fervenza, MD (2) · Frits van Rhee, MD (2)
PMID 35985959, PMID 37022569, PMID 40444214, PMID 26308596, PMID 33357481, PMID 35876974, PMID 27307294, PMID 30536810, PMID 31221782, PMID 32244252, PMID 32470437, PMID 33513030, PMID 33588922, PMID 34289038, PMID 36882409, PMID 38048391, PMID 38649340, PMID 39229471, PMID 41627370, PMID 16195338, PMID 19141862, PMID 21719599, PMID 22442346, PMID 24900946, PMID 25482239, PMID 25760767, PMID 25798669, PMID 25966987, PMID 25999452, PMID 26147651, PMID 26778538, PMID 27216216, PMID 27269947, PMID 27557302, PMID 27618682, PMID 27702799, PMID 27705267, PMID 27913532, PMID 28494052, PMID 28637662, PMID 28734759, PMID 29025767, PMID 29127588, PMID 29260507, PMID 29305553, PMID 29355075, PMID 29358182, PMID 29445583, PMID 29884853, PMID 30037340
2023 (22), 2017 (9), 2016 (8), 2019 (7), 2018 (6), 2025 (6), 2014 (4), U10CA180820 (4), 2015 (3), U10CA180888 (3), P30CA015083 (2), P30CA016672 (2), P30CA033572 (2), P30CA138292 (2), P30CA046934 (1)